Three things to know:
1. The orthopedic implant manufacturer recently received FDA-approval to launch an investigation device exemption clinical study in the U.S. to evaluate its BioPoly RS Partial Resurfacing Knee implant.
2. The BioPoly material is designed to function like an artificial cartilage because of its patented combination of a molecule found in cartilage with a polyethylene-based plastic. The material is intended to replace the damaged cartilage rather than the entire joint.
3. Since 2012, patients in Europe have received the implants.
More articles on devices:
Shift to outpatient setting drives global orthopedic implants market — 5 insights
Xtant Medical names new COO: 4 things to know
Spinal fusion devices make up 58% of products market — 10 key players
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.